Combating bacteria and drug resistance by inhibiting mechanisms of persistence and adaptation

Nature Chemical Biology

Volumn 3, Issue 9, 2007, Pages 549-556

  Smith, Peter A ^a   Romesberg, Floyd E ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; BETA LACTAM ANTIBIOTIC; CIPROFLOXACIN; METICILLIN; NORFLOXACIN; PSEUDOMONIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SHIGA TOXIN; TETRACYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BRONCHITIS; DNA REPAIR; DNA REPLICATION; DNA TRANSFER; ENTEROHEMORRHAGIC ESCHERICHIA COLI; GENE MUTATION; LUNG TUBERCULOSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MISMATCH REPAIR; MOUSE STRAIN; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; SEPSIS; STREPTOCOCCUS PNEUMONIAE;

BACTERIA (MICROORGANISMS);

EID: 34548094623     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.2007.27     Document Type: Review

References (99)

1. Lipsitch, M. & Samore, M.H. Antimicrobial use and antimicrobial resistance: a population perspective. Emerg. Infect. Dis. 8, 347-354 (2002).
2. Rice, L.B. Antimicrobial resistance in gram-positive bacteria. Am. J. Infect. Control 34 (suppl. 1), S11-19; discussion S64-73 (2006).
3. Wright, A. et al. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs - worldwide, 2000-2004. MMWR Morb. Mortal. Wkly. Rep. 55, 301-305 (2006).
4. Payne, D.J., Gwynn, M.N., Holmes, D.J. & Pompliano, D.L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6, 29-40 (2007).
5. Talbot, G.H. et al. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin. Infect. Dis. 42, 657-668 (2006).
6. Jin, D.J. & Gross, C.A. Mapping and sequencing of mutations in the Escherichia coli rpoB gene that lead to rifampicin resistance. J. Mol. Biol. 202, 45-58 (1988).
7. Drlica, K. & Zhao, X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev. 61, 377-392 (1997).
8. Zhang, Y. & Young, D. Molecular genetics of drug resistance in Mycobacterium tuberculosis. J. Antimicrob. Chemother. 34, 313-319 (1994).
9. Woodford, N. & Ellington, M.J. The emergence of antibiotic resistance by mutation. Clin. Microbiol. Infect. 13, 5-18 (2007).
10. Miller, J.H. Spontaneous mutators in bacteria: insights into pathways of mutagenesis and repair. Annu. Rev. Microbiol. 50, 625-643 (1996).
11. Cirz, R.T. & Romesberg, F.E. Induction and inhibition of ciprofloxacin resistance-conferring mutations in hypermutator bacteria. Antimicrob. Agents Chemother. 50, 220-225 (2006).
12. LeClerc, J.E., Li, B., Payne, W.L. & Cebula, T.A. High mutation frequencies among Escherichia coli and Salmonella pathogens. Science 274, 1208-1211 (1996).
13. Oliver, A., Canton, R., Campo, P., Baquero, F. & Blazquez, J. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288, 1251-1254 (2000).
14. Montanari, S. et al. Biological cost of hypermutation in Pseudomonas aeruginosa strains from patients with cystic fibrosis. Microbiology 153, 1445-1454 (2007).
15. Funchain, P. et al. The consequences of growth of a mutator strain of Escherichia coli as measured by loss of function among multiple gene targets and loss of fitness. Genetics 154, 959-970 (2000).
16. Giraud, A. et al. Costs and benefits of high mutation rates: adaptive evolution of bacteria in the mouse gut. Science 291, 2606-2608 (2001).
17. Harris, R.S., Longerich, S. & Rosenberg, S.M. Recombination in adaptive mutation. Science 264, 258-260 (1994).
18. Cairns, J. & Foster, P.L. Adaptive reversion of a frameshift mutation in Escherichia coli. Genetics 128, 695-701 (1991).
19. Foster, P.L., Trimarchi, J.M. & Maurer, R.A. Two enzymes, both of which process recombination intermediates, have opposite effects on adaptive mutation in Escherichia coli. Genetics 142, 25-37 (1996).
20. Harris, R.S., Ross, K.J. & Rosenberg, S.M. Opposing roles of the holliday junction processing systems of Escherichia coli in recombination-dependent adaptive mutation. Genetics 142, 681-691 (1996).
21. McKenzie, G.J., Lombardo, M.J. & Rosenberg, S.M. Recombination- dependent mutation in Escherichia coli occurs in stationary phase. Genetics 149, 1163-1165 (1998).
22. McKenzie, G.J., Harris, R.S., Lee, P.L. & Rosenberg, S.M. The SOS response regulates adaptive mutation. Proc. Natl. Acad. Sci. USA 97, 6646-6651 (2000).
23. Cirz, R.T. et al. Inhibition of mutation and combating the evolution of antibiotic resistance. PLoS Biol. 3, e176 (2005).
24. Miller, C. et al. SOS response induction by beta-lactams and bacterial defense against antibiotic lethality. Science 305, 1629-1631 (2004).
25. Riesenfeld, C., Everett, M., Piddock, L.J. & Hall, B.G. Adaptive mutations produce resistance to ciprofloxacin. Antimicrob. Agents Chemother. 41, 2059-2060 (1997).
26. Alonso, A., Campanario, E. & Martinez, J.L. Emergence of multidrug-resistant mutants is increased under antibiotic selective pressure in Pseudomonas aeruginosa. Microbiology 145, 2857-2862 (1999).
27. Boshoff, H.I., Reed, M.B., Barry, C.E. III & Mizrahi, V. DnaE2 polymerase contributes to in vivo survival and the emergence of drug resistance in Mycobacterium tuberculosis. Cell 113, 183-193 (2003).
28. Taddei, F. et al. Role of mutator alleles in adaptive evolution. Nature 387, 700-702 (1997).
29. Joo, L.M., Macfarlane-Smith, L.R. & Okeke, I.N. Error-prone DNA repair system in enteroaggregative Escherichia coli identified by subtractive hybridization. J. Bacteriol. 189, 3793-3803 (2007).
30. Bilello, J.A., Bauer, G., Dudley, M.N., Cole, G.A. & Drusano, G.L. Effect of 2′,3′-didehydro-3′-deoxythymidine in an in vitro hollow-fiber pharmacodynamic model system correlates with results of dose-ranging clinical studies. Antimicrob. Agents Chemother. 38, 1386-1391 (1994).
31. Paterson, D.L. & Bonomo, R.A. Extended-spectrum beta-lactamases: a clinical update. Clin. Microbiol. Rev. 18, 657-686 (2005).
32. Weigel, L.M. et al. Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus. Science 302, 1569-1571 (2003).
33. Fosheim, G.E., Carey, R.B. & Limbago, B.M. Evaluation of the AdvanDx VRE EVIGENE assay for detection of vanA in vancomycin-resistant Staphylococcus aureus. J. Clin. Microbiol. 45, 1611-1613 (2007).
34. Cao, T.B. & Saier, M.H. Jr. Conjugal type IV macromolecular transfer systems of Gram-negative bacteria: organismal distribution, structural constraints and evolutionary conclusions. Microbiology 147, 3201-3214 (2001).
35. Cascales, E. & Christie, P.J. Definition of a bacterial type IV secretion pathway for a DNA substrate. Science 304, 1170-1173 (2004).
36. Yeo, H.J. & Waksman, G. Unveiling molecular scaffolds of the type IV secretion system. J. Bacteriol. 186, 1919-1926 (2004).
37. Frost, L.S., Leplae, R., Summers, A.O. & Toussaint, A. Mobile genetic elements: the agents of open source evolution. Nat. Rev. Microbiol. 3, 722-732 (2005).
38. Hilleringmann, M. et al. Inhibitors of Helicobacter pylori ATPase Cagα block CagA transport and cag virulence. Microbiology 152, 2919-2930 (2006).
39. Backert, S. et al. Translocation of the Helicobacter pylori CagA protein in gastric epithelial cells by a type IV secretion apparatus. Cell. Microbiol. 2, 155-164 (2000).
40. Odenbreit, S. et al. Translocation of Helicobacter pylori CagA into gastric epithelial cells by type IV secretion. Science 287, 1497-1500 (2000).
41. Grohmann, E., Muth, G. & Espinosa, M. Conjugative plasmid transfer in gram-positive bacteria. Microbiol. Mol. Biol. Rev. 67, 277-301 (2003).
42. Chen, I. & Dubnau, D. DNA uptake during bacterial transformation. Nat. Rev. Microbiol. 2, 241-249 (2004).
43. Fernandez-Lopez, R. et al. Unsaturated fatty acids are inhibitors of bacterial conjugation. Microbiology 151, 3517-3526 (2005).
44. Hurdle, J.G., O'Neill, A.J., Mody, L., Chopra, I. & Bradley, S.F. In vivo transfer of high-level mupirocin resistance from Staphylococcus epidermidis to methicillin-resistant Staphylococcus aureus associated with failure of mupirocin prophylaxis. J. Antimicrob. Chemother. 56, 1166-1168 (2005).
45. Beaber, J.W., Hochhut, B. & Waldor, M.K. SOS response promotes horizontal dissemination of antibiotic resistance genes. Nature 427, 72-74 (2004).
46. Moritz, E.M. & Hergenrother, P.J. Toxin-antitoxin systems are ubiquitous and plasmid-encoded in vancomycin-resistant enterococci. Proc. Natl. Acad. Sci. USA 104, 311-316 (2007).
47. Engelberg-Kulka, H., Sat, B., Reches, M., Amitai, S. & Hazan, R. Bacterial programmed cell death systems as targets for antibiotics. Trends Microbiol. 12, 66-71 (2004).
48. Gerdes, K., Christensen, S.K. & Lobner-Olesen, A. Prokaryotic toxin-antitoxin stress response loci. Nat. Rev. Microbiol. 3, 371-382 (2005).
49. Gamage, S.D., Strasser, J.E., Chalk, C.L. & Weiss, A.A. Nonpathogenic Escherichia coli can contribute to the production of Shiga toxin. Infect. Immun. 71, 3107-3115 (2003).
50. Fuchs, S. et al. Influence of RecA on in vivo virulence and Shiga toxin 2 production in Escherichia coli pathogens. Microb. Pathog. 27, 13-23 (1999).
51. Sumby, P. & Waldor, M.K. Transcription of the toxin genes present within the Staphylococcal phage φSa3ms is intimately linked with the phage's life cycle. J. Bacteriol. 185, 6841-6851 (2003).
52. Hastings, P.J., Rosenberg, S.M. & Slack, A. Antibiotic-induced lateral transfer of antibiotic resistance. Trends Microbiol. 12, 401-404 (2004).
53. Fish, D.N., Piscitelli, S.C. & Danziger, L.H. Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies. Pharmacotherapy 15, 279-291 (1995).
54. Hobby, G.L., Meyer, K. & Chaffee, E. Observations on the mechanism of action of penicillin. Proc. Soc. Exp. Biol. Med. 50, 281-285 (1942).
55. Keren, I., Shah, D., Spoering, A., Kaldalu, N. & Lewis, K. Specialized persister cells and the mechanism of multidrug tolerance in Escherichia coli. J. Bacteriol. 186, 8172-8180 (2004).
56. Wiuff, C. et al. Phenotypic tolerance: antibiotic enrichment of noninherited resistance in bacterial populations. Antimicrob. Agents Chemother. 49, 1483-1494 (2005).
57. Levin, B.R. & Rozen, D.E. Non-inherited antibiotic resistance. Nat. Rev. Microbiol. 4, 556-562 (2006).
58. Smith, A.L., Fiel, S.B., Mayer-Hamblett, N., Ramsey, B. & Burns, J.L. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 123, 1495-1502 (2003).
59. Dworzack, D.L., Pugsley, M.P., Sanders, C.C. & Horowitz, E.A. Emergence of resistance in gram-negative bacteria during therapy with expanded-spectrum cephalosporins. Eur. J. Clin. Microbiol. 6, 456-459 (1987).
60. Tuomanen, E., Durack, D.T. & Tomasz, A. Antibiotic tolerance among clinical isolates of bacteria. Antimicrob. Agents Chemother. 30, 521-527 (1986).
61. Lewis, K. Persister cells, dormancy and infectious disease. Nat. Rev. Microbiol. 5, 48-56 (2007).
62. Gilbert, P., Collier, P.J. & Brown, M.R. Influence of growth rate on susceptibility to antimicrobial agents: biofilms, cell cycle, dormancy, and stringent response. Antimicrob. Agents Chemother. 34, 1865-1868 (1990).
63. Rogers, H.J. The killing of bacteria by cell wall inhibitors. Contrib. Microbiol. Immunol. 1, 117-134 (1973).
64. Vazquez-Laslop, N., Lee, H. & Neyfakh, A.A. Increased persistence in Escherichia coli caused by controlled expression of toxins or other unrelated proteins. J. Bacteriol. 188, 3494-3497 (2006).
65. Shah, D. et al. Persisters: a distinct physiological state of E. coli. BMC Microbiol. 6, 53 (2006).
66. Keren, I., Kaldalu, N., Spoering, A., Wang, Y. & Lewis, K. Persister cells and tolerance to antimicrobials. FEMS Microbiol. Lett. 230, 13-18 (2004).
67. Moyed, H.S. & Bertrand, K.P. hipA, a newly recognized gene of Escherichia coli K-12 that affects frequency of persistence after inhibition of murein synthesis. J. Bacteriol. 155, 768-775 (1983).
68. Falla, T.J. & Chopra, I. Stabilization of Rhizobium symbiosis plasmids. Microbiology 145, 515-516 (1999).
69. Buts, L., Lah, J., Dao-Thi, M.H., Wyns, L. & Loris, R. Toxin-antitoxin modules as bacterial metabolic stress managers. Trends Biochem. Sci. 30, 672-679 (2005).
70. Pedersen, K. et al. The bacterial toxin RelE displays codon-specific cleavage of mRNAs in the ribosomal A site. Cell 112, 131-140 (2003).
71. Christensen, S.K., Pedersen, K., Hansen, F.G. & Gerdes, K. Toxin-antitoxin loci as stress-response-elements: ChpAK/MazF and ChpBK cleave translated RNAs and are counteracted by tmRNA. J. Mol. Biol. 332, 809-819 (2003).
72. Pandey, D.P. & Gerdes, K. Toxin-antitoxin loci are highly abundant in free-living but lost from host-associated prokaryotes. Nucleic Acids Res. 33, 966-976 (2005).
73. Pedersen, K., Christensen, S.K. & Gerdes, K. Rapid induction and reversal of a bacteriostatic condition by controlled expression of toxins and antitoxins. Mol. Microbiol. 45, 501-510 (2002).
74. Black, D.S., Irwin, B. & Moyed, H.S. Autoregulation of hip, an operon that affects lethality due to inhibition of peptidoglycan or DNA synthesis. J. Bacteriol. 176, 4081-4091 (1994).
75. Korch, S.B., Henderson, T.A. & Hill, T.M. Characterization of the hipA7 allele of Escherichia coli and evidence that high persistence is governed by (p)ppGpp synthesis. Mol. Microbiol. 50, 1199-1213 (2003).
76. Li, Y. & Zhang, Y. PhoU is a persistence switch involved in persister formation and tolerance to multiple antibiotics and stresses in Escherichia coli. Antimicrob. Agents Chemother. 51, 2092-2099 (2007).
77. Tsilibaris, V., Maenhaut-Michel, G., Mine, N. & Van Melderen, L. What is the benefit for E. coli to have multiple toxin-antitoxin systems in their genomes? J. Bacteriol., published online 18 May 2007 (doi:10.1128/JB.00527-07).
78. Korch, S.B. & Hill, T.M. Ectopic overexpression of wild-type and mutant hipA genes in Escherichia coli: effects on macromolecular synthesis and persister formation. J. Bacteriol. 188, 3826-3836 (2006).
79. Correia, F.F. et al. Kinase activity of overexpressed HipA is required for growth arrest and multidrug tolerance in Escherichia coli. J. Bacteriol. 188, 8360-8367 (2006).
80. Spoering, A.L., Vulic, M. & Lewis, K. GlpD and PlsB participate in persister cell formation in Escherichia coli. J. Bacteriol. 188, 5136-5144 (2006).
81. Young, D., Hussell, T. & Dougan, G. Chronic bacterial infections: living with unwanted guests. Nat. Immunol. 3, 1026-1032 (2002).
82. Coates, A., Hu, Y., Bax, R. & Page, C. The future challenges facing the development of new antimicrobial drugs. Nat. Rev. Drug Discov. 1, 895-910 (2002).
83. Smith, I. Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. Clin. Microbiol. Rev. 16, 463-496 (2003).
84. Fritz, C., Maass, S., Kreft, A. & Bange, F.C. Dependence of Mycobacterium bovis BCG on anaerobic nitrate reductase for persistence is tissue specific. Infect. Immun. 70, 286-291 (2002).
85. McKinney, J.D. et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 406, 735-738 (2000).
86. Fang, F.C., Libby, S.J., Castor, M.E. & Fung, A.M. Isocitrate lyase (AceA) is required for Salmonella persistence but not for acute lethal infection in mice. Infect. Immun. 73, 2547-2549 (2005).
87. Palmer, K.L., Brown, S.A. & Whiteley, M. Membrane-bound nitrate reductase is required for anaerobic growth in cystic fibrosis sputum. J. Bacteriol. 189, 4449-4455 (2007).
88. Cho, S.H. et al. Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 51, 1380-1385 (2007).
89. Smith, E.E. et al. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc. Natl. Acad. Sci. USA 103, 8487-8492 (2006).
90. Mwangi, M.M. et al. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc. Natl. Acad. Sci. USA 104, 9451-9456 (2007).
91. Perez-Capilla, T. et al. SOS-independent induction of dinB transcription by beta-lactam-mediated inhibition of cell wall synthesis in Escherichia coli. J. Bacteriol. 187, 1515-1518 (2005).
92. Roy-Burman, A. et al. Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. J. Infect. Dis. 183, 1767-1774 (2001).
93. Jain, M. et al. Type III secretion phenotypes of Pseudomonas aeruginosa strains change during infection of individuals with cystic fibrosis. J. Clin. Microbiol. 42, 5229-5237 (2004).
94. Skinner, J.A., Pilione, M.R., Shen, H., Harvill, E.T. & Yuk, M.H. Bordetella type III secretion modulates dendritic cell migration resulting in immunosuppression and bacterial persistence. J. Immunol. 175, 4647-4652 (2005).
95. Troisfontaines, P. & Cornelis, G.R. Type III secretion: more systems than you think. Physiology (Bethesda) 20, 326-339 (2005).
96. Silver, L.L. Multi-targeting by monotherapeutic antibacterials. Nat. Rev. Drug Discov. 6, 41-55 (2007).
97. Gentry, D.R. et al. Variable sensitivity to bacterial methionyl-tRNA synthetase inhibitors reveals subpopulations of Streptococcus pneumoniae with two distinct methionyl-tRNA synthetase genes. Antimicrob. Agents Chemother. 47, 1784-1789 (2003).
98. Heath, R.J. & Rock, C.O. A triclosan-resistant bacterial enzyme. Nature 406, 145-146 (2000).
99. Frank, A.C., Alsmark, C.M., Thollesson, M. & Andersson, S.G. Functional divergence and horizontal transfer of type IV secretion systems. Mol. Biol. Evol. 22, 1325-1336 (2005).